News | March 20, 2024
AstraZeneca buys biopharmaceutical company Fusion
To accelerate the development of next-generation radioconjugates to treat cancer
To accelerate the development of next-generation radioconjugates to treat cancer
Ukrainian marketing approvals for paclitaxel, oxaliplatin and irinotecan mark a significant milestone in the company’s global expansion strategy
Versavo is the first Dr. Reddy's biosimilar product to be approved and launched in the UK
Acquisition to further expand the Alexion, AstraZeneca Rare Disease pipeline beyond complement inhibition
Christoph Funke's extensive career includes leadership roles at organizations such as Fresenius Kabi and Strides Pharma Science
The first and only oral androgen deprivation therapy treatment for men with advanced prostate cancer
The drug will target specific genetic mutations prevalent in certain types of cancers
New institute brings together Evonik’s most advanced biotech platform and a global network of evaluation labs
Acquisition broadens oncology pipeline with a portfolio of novel T-cell engagers including HPN328 (MK-6070), an investigational delta-like ligand 3 (DLL3) targeting T-cell engager
The validations confirm the completion of the applications and commence the scientific review process
Subscribe To Our Newsletter & Stay Updated
